-1-1.png)
Seeking to mitigate increasing supply chain risks, pharmaceutical companies have identified “China Plus One” as a strategic imperative. Under this risk-management model, companies diversify their supply chains to include at least one other country in addition to China, allowing them to continue benefitting from China';s manufacturing footprint while avoiding the risks associated with relying solely on one country.
-3.png)
Cryogenic reactions are essential for synthesizing certain active pharmaceutical ingredients (APIs), enabling chemists to reduce impurities, ensure safety, improve selectivity, and facilitate reactions that are impossible at higher temperatures. The advantages of cryogenic conditions make them critical to the development and production of life-changing medicines.
-2-1.png)
An increased focus on targeted therapeutics has driven rapid growth in the Highly Potent Active Pharmaceutical Ingredients (HPAPIs) segment of the pharmaceutical industry. The surge in antibody-drug conjugates (ADCs) boosts that forecast even further since their core active component, the payload, is typically classified as an HPAPI.
High-throughput experimentation (HTE) empowers drug developers to quickly build robust platforms for scale-up. Facing constraints on their time, resources, and materials, companies leverage this approach to rapidly execute many miniaturized reactions in parallel to survey a wide range of possible reaction conditions.
At Piramal Pharma Solutions, we are dedicated to continuous improvement, consistently refining our processes to optimize project execution and delivery. In line with this commitment, the leadership team at our drug substance site in Aurora, Canada developed the POD system, which brings greater structure, ownership, and adaptability to project execution. By integrating the POD system into our existing project management processes, Aurora is well-equipped to support a robust pipeline of demanding projects, with a strong focus on flawless delivery.
-2.png)
.png)
